home / stock / dmac / dmac quote
Last: | $2.95 |
---|---|
Change Percent: | -1.31% |
Open: | $3.09 |
Close: | $2.95 |
High: | $3.09 |
Low: | $2.875 |
Volume: | 39,311 |
Last Trade Date Time: | 06/28/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.95 | $3.09 | $2.95 | $3.09 | $2.875 | 39,311 | 06-28-2024 |
$3.05 | $2.99 | $3.05 | $3.05 | $2.74 | 77,682 | 06-27-2024 |
$2.96 | $2.58 | $2.96 | $3.24 | $2.49 | 1,179,326 | 06-26-2024 |
$2.26 | $2.27 | $2.26 | $2.378 | $2.24 | 23,855 | 06-25-2024 |
$2.22 | $2.14 | $2.22 | $2.2909 | $2.14 | 28,253 | 06-24-2024 |
$2.16 | $2.33 | $2.16 | $2.35 | $2.16 | 29,505 | 06-21-2024 |
$2.28 | $2.35 | $2.28 | $2.4 | $2.27 | 38,627 | 06-20-2024 |
$2.32 | $2.3599 | $2.32 | $2.44 | $2.3 | 27,386 | 06-19-2024 |
$2.32 | $2.3599 | $2.32 | $2.44 | $2.3 | 27,386 | 06-18-2024 |
$2.39 | $2.41 | $2.39 | $2.42 | $2.25 | 21,248 | 06-17-2024 |
$2.4 | $2.35 | $2.4 | $2.5 | $2.34 | 22,220 | 06-14-2024 |
$2.35 | $2.43 | $2.35 | $2.5428 | $2.32 | 65,061 | 06-13-2024 |
$2.51 | $2.57 | $2.51 | $2.68 | $2.5 | 25,168 | 06-12-2024 |
$2.61 | $2.55 | $2.61 | $2.61 | $2.5 | 20,839 | 06-11-2024 |
$2.6 | $2.58 | $2.6 | $2.68 | $2.58 | 15,264 | 06-10-2024 |
$2.56 | $2.7 | $2.56 | $2.82 | $2.56 | 24,348 | 06-07-2024 |
$2.73 | $2.88 | $2.73 | $2.88 | $2.68 | 35,114 | 06-06-2024 |
$2.88 | $2.87 | $2.88 | $2.9 | $2.8028 | 6,774 | 06-05-2024 |
$2.82 | $2.88 | $2.82 | $2.88 | $2.8 | 23,787 | 06-04-2024 |
$2.95 | $2.925 | $2.95 | $2.96 | $2.8701 | 7,927 | 06-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
DiaMedica Therapeutics Inc. Company Name:
DMAC Stock Symbol:
NASDAQ Market:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced that it has entered into definitive agreements to sell its common shares in a private placement with accredited investors. Th...
Preeclampsia Program to be Initiated with a Phase 2 Investigator-sponsored Trial Beginning in Q4 2024 Key Proof-of-Concept Results Expected in the First Half of 2025 Management will Host a Conference Call Thursday, June 27, 2024 at 8:00 AM Eastern Time / 7:00 AM Central Time to Di...